Default Category
-
Laree Verbindungen GmbH
Ariño, Miguel Angel; Heukamp, FranzCase AD-361Decision AnalysisLaree es una compañía alemana que fabrica y suministra las fijaciones que se utilizan en las construcciones para sujetar los vidrios a las paredes de los edificios. Sus ejecutivos deben decidir si aceptar un contrato que podría ser una gran oportunidad para abrir un nuevo mercado para la empresa o resultar en una pérdida importante de dinero. Este caso está basado en el caso "Berfest AG" de los mismos autores (AD-314) y en el caso Thurman Indust...Starting at €8.20
-
Laree Verbindungen GmbH
Ariño, Miguel Angel; Heukamp, FranzCase AD-361-EDecision AnalysisLaree is a German company that manufactures and supplies the fasteners that are used in construction to attach glass to the walls of buildings. Its executives must decide whether to accept a contract that could be a great opportunity to open a new market for the company or result in a significant loss of money. This case is based on the "Berfest AG" case by the same authors. This case replaces The Berfest case from the same authors (AD-314).Starting at €8.20
-
Laree Verbindungen GmbH (Portuguese Version, Brazil)
Ariño, Miguel Angel; Heukamp, FranzCase AD-361-PBDecision AnalysisLaree is a German company that manufactures and supplies the fasteners that are used in construction to attach glass to the walls of buildings. Its executives must decide whether to accept a contract that could be a great opportunity to open a new market for the company or result in a significant loss of money. This case is based on the "Berfest AG" case by the same authors. This case replaces The Berfest case from the same authors (AD-314).Starting at €8.20
-
ERBITUX: A Miracle Drug Or Just a Lot of Headaches
Heukamp, Franz; Ariño, Miguel AngelCase AD-347-EDecision AnalysisIn February of 2002, Bernhard Scheuble, the CEO of Merck, received news that the U.S. Food and Drug Administration had "refused to file" Erbitux, a new "miracle" cancer treatment drug. The drug was supposed to have represented Merck's entry into the field of oncology. Erbitux had been an enormous gamble for the first non-family CEO in Merck's 350-year history. It had refocused the company's operations on an entirely new field: oncology. Adding to...Starting at €8.20
-
Dan McCrum - Unmasking Wirecard
Heese, Jonas; Wang, Charles C.Y.; Labruyere, Tonia; Moniz, CarlotaCase HBS-123098-EAccounting and ControlDan McCrum, an investigative journalist for the Financial Times, had spent the past six years fighting to expose German payment processing firm Wirecard. The company had enjoyed years of exponential growth and was viewed by several investors as the poster child of Germany's tech sector. But to McCrum something smelled fishy and he couldn't help but wonder if Wirecard's true dealings weren't just hidden behind its complex business model. He starte...Starting at €8.20